Latest news on CML: Can targeted therapy with bosutinib cure it?

Bosutinib (Bosutinib) is a targeted drug that can be used to treat specific types of leukemia, such as chronic myeloid leukemia (CML). However, there is currently no drug that can be called a complete cure for leukemia. Bosutinib can help control the development of leukemia, reduce symptoms and extend survival, but it cannot eliminate leukemia cells. Therefore, treating leukemia is usually a long-term process that may need to be combined with other treatments to achieve optimal results.

The treatment of chronic myelogenous leukemia requires comprehensive treatment under the guidance of a doctor, including drug treatment, observation of disease progression, and adjustment of treatment plans. Bosutinib has been shown to improve outcomes in patients with chronic myelogenous leukemia, including reducing the number of Philadelphia chromosome cancer cells and normalizing white blood cell levels. The side effects of this drug are considered manageable and may cause adverse reactions such as diarrhea, nausea, abdominal pain, vomiting, rash, fatigue, fever, and headache.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of the Turkish version may be more than RMB 2,000 per box of 500mg*28, and the price of the European version may be more than RMB 30,000 (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.